Stocks Trending Alert: Energy Transfer Equity, L.P. (ETE), American Airlines Group Inc. (AAL), AbbVie Inc. (ABBV)

Energy Transfer Equity, L.P. (ETE) saw its value decrease by -1.24% as the stock dropped $-0.24 to finish the day at a closing price of $19.12. The stock was lighter in trading and has fluctuated between $5.94-$20.05 per share for the past year. The shares, which traded within a range of $19.06 to $19.54 during the day, are up by 15.18% in the past three months and up by 11.9% over the past six months. It is currently trading 3.43% above its 20 day moving average and 4.78% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $19.84 a share over the next twelve months. The current relative strength index (RSI) reading is 57.24.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Energy Transfer Equity, L.P. provides diversified energy-related services in the Unites States. It owns and operates approximately 7,500 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas; and approximately 12,300 miles of interstate natural gas pipelines. The company sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. Its midstream operations include ownership and operation of approximately 35,000 miles of in service natural gas pipelines, 31 natural gas processing plants, 21 natural gas treating facilities, and 4 natural gas conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, and Louisiana; operation of natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas, as well as a natural gas gathering system in Ohio; and transportation and supply of water to natural gas producers in Pennsylvania. The company’s natural gas liquid (NGL) transportation and services operations include ownership of approximately 2,000 miles of NGL pipelines, three NGL processing plants, four NGL and propane fractionation facilities, and NGL storage facilities. It also sells gasoline and middle distillates at retail; operates convenience stores primarily on the east coast and in the Midwest region of the United States; and gathers, purchases, stores, transports, markets, and sells crude oil, NGLs, and refined products. In addition, it provides natural gas compression services; treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration, and British thermal unit management services; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalties, and generates a total of 75 megawatts electrical power. The company was founded in 2002 and is based in Dallas, Texas.

American Airlines Group Inc. (AAL) shares were down in last trading by -1.2% to $46.97. It experienced lighter than average volume on day. The stock increased in value by almost 1.45% over the past week and fell -1.19% in the past month. It is currently trading -0.17% below its 50 day moving average and 21.57% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -7.04% decrease in value from its one year high of $50.64. The RSI indicator value of 52.59, lead us to believe that it is a hold for now.

American Airlines Group Inc., through its subsidiaries, operates in the airline industry. As of December 31, 2015, the company operated a mainline fleet of 946 aircraft. It serves 350 destinations in approximately 50 countries. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1934 and is headquartered in Fort Worth, Texas.

AbbVie Inc. (ABBV) traded within a range of $60.81 to $61.91 after opening the day at $61.67. The company has seen its stock decrease in value by -0.83% so far this year. The stock was down close to -0.28% on light volume in last trading session and closed at $61.48 per share. After the recent fall, the stock is currently holding -8% below its 52 week high of $68.12 and 21.05% above its 12-month low of $53.74. The shares are down by over -1.22% in the last three months, and the RSI indicator value of 54.64 is neither bullish nor bearish, tempting investors to stay on the sidelines.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

 

Stocks in Focus: Bristol-Myers Squibb Company (BMY), Corning Incorporated (GLW), AbbVie Inc. (ABBV)

Bristol-Myers Squibb Company (BMY) had a active trading with around 5.84M shares changing hands compared to its three month average trading volume of 11.97M. The stock traded between $51.52 and $51.97 before closing at the price of $51.65 with 0.27% change on the day. The New York New York 10154 based company is currently trading 12.26% above its 52 week low of $46.01 and -32.12% below its 52 week high of $77.12. Both the RSI indicator and target price of 46.4 and $55.18 respectively, lead us to believe that it should be put on hold over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corning Incorporated (GLW) failed to extend gains with the stock declining -0.37% or $-0.1 to close the day at $26.7 on light trading volume of 5.81M shares, compared to its three month average trading volume of 7.25M. The Corning New York 14831 based company has been outperforming the diversified electronics group over the past 52 weeks, with the stock gaining 53.83%, compared to the industry which has advanced 45.27% over the same period. With RSI of 65.39, the stock should still continue to rise and get closer to its one year target estimate of $26.5, making it a hold for now.

Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials in North America, the Asia Pacific, Europe, and internationally. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for liquid crystal displays (LCDs) used in LCD televisions, notebook computers, and flat panel desktop monitors. The Optical Communications segment manufactures optical fiber and cable; and hardware and equipment products comprising cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories for various carrier network applications. This segment also offers subscriber demarcation, connection and protection devices, passive solutions, and outside plant enclosures; and coaxial RF interconnects for the cable television industry and microwave applications. The Environmental Technologies segment manufactures ceramic substrates and filter products for emissions control in mobile and stationary, and gasoline and diesel applications. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals. The Life Sciences segment manufactures and supplies scientific laboratory products consisting of consumables, such as plastic vessels, specialty surfaces, and media, as well as general labware and equipment for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry; and develops and produces technologies for biologic drug production markets. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

AbbVie Inc. (ABBV) shares were down in last trading by -0.69% to $60.42. It experienced lighter than average volume on day. The stock decreased in value by almost -0.41% over the past week and fell -1.18% in the past month. It is currently trading -1.29% below its 50 day moving average and -1.52% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -9.58% decrease in value from its one year high of $68.12. The RSI indicator value of 42.55, lead us to believe that it is a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

 

Stocks on Trader’s Radar: Schlumberger Limited (SLB), AbbVie Inc. (ABBV), Delta Air Lines, Inc. (DAL)

Schlumberger Limited (SLB) managed to rebound with the stock climbing 0.06% or $0.05 to close the day at $81.12 on light trading volume of 5.36M shares, compared to its three month average trading volume of 5.53M. The Houston Texas 77056 based company has been outperforming the oil & gas equipment & services group over the past 52 weeks, with the stock gaining 22.8%, compared to the industry which has advanced 37.14% over the same period. With RSI of 32.48, the stock should still continue to rise and get closer to its one year target estimate of $96.79, making it a hold for now.

Schlumberger Limited supplies technology products and services to the oil and gas exploration and production industry worldwide. Its Reservoir Characterization Group segment provides reservoir imaging, monitoring, and development services; wireline technologies for open and cased-hole services; slickline services; exploration and production pressure and flow-rate measurement services comprising surface and downhole services; software integrated solutions, such as software, consulting, information management, and IT infrastructure services; consulting services for reservoir characterization, field development planning, and production enhancement; and petrotechnical data services and training solutions, as well as integrated management services. Its Drilling Group segment designs, manufactures, and markets roller cone and fixed cutter drill bits; supplies drilling fluid systems; provides pressure drilling and underbalanced drilling solutions, and environmental services and products; mud logging services; land drilling rigs and support services; and well planning and drilling, engineering, supervision, logistics, procurement, contracting, and drilling rig management services, as well as bottom-hole-assembly, borehole-enlargement technologies, impact tools, tubulars, and tubular services. Its Production Group segment provides well services comprising pressure pumping, well cementing, and stimulation services; coiled tubing equipment; well completion services and equipment that include packers, safety valves, and sand control technology, as well as completions technology and equipment; artificial lifts; and integrated production and production management services. Its Cameron Group segment offers integrated subsea production systems; surface systems; drilling equipment and services; and valve products and measurement systems. The company was formerly known as Socie´te´ de Prospection E´lectrique. Schlumberger Limited was founded in 1926 and is based in Houston, Texas.

AbbVie Inc. (ABBV) fell -0.07% during last trading as the stock lost $-0.04 to finish the day at $60.52 with about 5.36M shares changing hands, compared to its three month average trading volume of 7.58M. The $98.71B market cap company, which fluctuated between $60.05 and $61.02 during the day, currently situated 21.77% above its 52 week low of $51.6 and -9.43% away from its one year high of $68.12. The RSI of 44.36 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Delta Air Lines, Inc. (DAL) saw its value decrease by -0.1% as the stock dropped $-0.05 to finish the day at a closing price of $48.1. The stock was lighter in trading and has fluctuated between $32.6-$52.76 per share for the past year. The shares, which traded within a range of $47.73 to $48.3 during the day, are up by 9.3% in the past three months and up by 30.79% over the past six months. It is currently trading -2.64% below its 20 day moving average and -3.01% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $61.4 a share over the next twelve months. The current relative strength index (RSI) reading is 42.15. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its route network is centered around a system of hubs, international gateways, and airports in Amsterdam, Atlanta, Boston, Detroit, London-Heathrow, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including delta.com and mobile, telephone reservations, traditional brick and mortar, and online travel agencies. It also provides aircraft maintenance, repair, and overhaul services; staffing, and professional security and training services, as well as aviation solutions to third parties; vacation packages to third-party consumers; and aircraft charters, and aircraft management and programs. As of February 3, 2016, the company operated a fleet of approximately 800 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is headquartered in Atlanta, Georgia.

 

Stocks on Trader’s Radar: AbbVie Inc. (ABBV), eBay Inc. (EBAY), Corning Incorporated (GLW)

AbbVie Inc. (ABBV) continued its downward trend with the stock declining -0.03% or $-0.02 to close the day at $60.65 on light trading volume of 5.31M shares, compared to its three month average trading volume of 7.89M. The North Chicago Illinois 60064 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 18.54%, compared to the industry which has advanced 10.8% over the same period. With RSI of 44.62, the stock should still continue to rise and get closer to its one year target estimate of $70.11, making it a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

eBay Inc. (EBAY) fell -0.12% during last trading as the stock lost $-0.04 to finish the day at $32.03 with about 5.29M shares changing hands, compared to its three month average trading volume of 10.45M. The $35.7B market cap company, which fluctuated between $31.86 and $32.24 during the day, currently situated 48.84% above its 52 week low of $21.64 and -3.5% away from its one year high of $33.19. The RSI of 64.83 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

eBay Inc. operates e-commerce platforms that connect various buyers and sellers worldwide. Its platforms enable sellers to organize and offer inventory for sale; and buyers to find and buy it virtually anytime and anywhere. The company’s Marketplace platforms include its online marketplace at ebay.com and the eBay mobile apps; and StubHub platforms comprise its online ticket platform at stubhub.com and the StubHub mobile apps, which enable fans to purchase tickets to the games, concerts, and theater shows. Its Classifieds platforms include a collection of brands, such as Mobile.de, Kijiji, Gumtree, Marktplaats, eBay Classifieds, and others that offer online classifieds and help people find whatever they are looking for in their local communities. The company platforms enable users to find, buy, sell, and pay for items through various online, mobile, and offline channels, which include retailers, distributors, liquidators, import and export companies, auctioneers, catalog and mail-order companies, classifieds, directories, search engines, commerce participants, shopping channels, and networks. eBay Inc. was founded in 1995 and is headquartered in San Jose, California.

Corning Incorporated (GLW) saw its value decrease by -0.07% as the stock dropped $-0.02 to finish the day at a closing price of $26.71. The stock was lighter in trading and has fluctuated between $17.61-$26.99 per share for the past year. The shares, which traded within a range of $26.51 to $26.75 during the day, are up by 20.31% in the past three months and up by 19.37% over the past six months. It is currently trading 4.99% above its 20 day moving average and 7.83% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $26.5 a share over the next twelve months. The current relative strength index (RSI) reading is 68.83. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials worldwide. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for liquid crystal displays (LCDs) used in LCD televisions, notebook computers, and flat panel desktop monitors. The Optical Communications segment manufactures optical fiber and cable; and hardware and equipment products comprising cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories. This segment also offers subscriber demarcation, connection and protection devices, passive solutions, and outside plant enclosures; and coaxial RF interconnects for the cable television industry and microwave applications. The Environmental Technologies segment manufactures ceramic substrates and filter products for emissions control in mobile and stationary, and gasoline and diesel applications. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals. The Life Sciences segment manufactures and supplies scientific laboratory products consisting of consumables, such as plastic vessels, specialty surfaces, and media, as well as general labware and equipment for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry. It also engages in a pharmaceutical glass vessel and a tubing business; and precision materials’ non-LCD business, as well as precision laser cutting/shaping technologies, and flow reactors and adjacency businesses for glass. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

 

Stocks in Focus: AbbVie Inc. (ABBV), CA, Inc. (CA), Berkshire Hathaway Inc. (BRK-B)

AbbVie Inc. (ABBV) had a light trading with around 8.15M shares changing hands compared to its three month average trading volume of 8.18M. The stock traded between $59.75 and $61.31 before closing at the price of $61.11 with 1.13% change on the day. The North Chicago Illinois 60064 based company is currently trading 22.96% above its 52 week low of $51.6 and -8.55% below its 52 week high of $68.12. Both the RSI indicator and target price of 48.86 and $69.94 respectively, lead us to believe that it should be put on hold over the coming weeks.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

CA, Inc. (CA) managed to rebound with the stock climbing 0.45% or $0.14 to close the day at $31.27 on active trading volume of 3.29M shares, compared to its three month average trading volume of 2.6M. The New York New York 10022 based company has been outperforming the business software & services group over the past 52 weeks, with the stock gaining 13.56%, compared to the industry which has advanced 19.31% over the same period. With RSI of 38.27, the stock should still continue to rise and get closer to its one year target estimate of $32.8, making it a hold for now.

CA, Inc. provides information technology (IT) management software and solutions that help organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally. The company operates through three segments: Mainframe Solutions, Enterprise Solutions, and Services. The Mainframe Solutions segment’s products portfolio include databases and database management, systems and operations management, application development, and security and compliance. The Enterprise Solutions segment provides products that are designed for distributed and cloud computing environments and run on industry standard servers. It offers Agile management solutions, which enables customers to plan and manage software development process and IT services delivery; DevOps solutions comprising a range of solutions that allow customers to deliver and manage applications and IT infrastructure; and security solutions, such as identity-centric security portfolio that allows customers to manage identities and regulate access from the device to the data center. The Services segment offers consulting, implementation, application management services, education, and support services to commercial and government customers. The company serves banks, insurance companies, other financial services providers, government agencies, global service providers, telecommunication providers, manufacturers, technology companies, retailers, educational organizations, and health care institutions. CA, Inc. sells its solutions through direct sales force, as well as indirectly through its partners. The company was formerly known as CA Technologies and changed its name to CA, Inc. in 2006. CA, Inc. was founded in 1974 and is headquartered in New York, New York.

Berkshire Hathaway Inc. (BRK-B) shares were down in last trading by -0.4% to $164.14. It experienced lighter than average volume on day. The stock increased in value by almost 2.13% over the past week and grew 0.67% in the past month. It is currently trading 1.23% above its 50 day moving average and 9.91% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -1.86% decrease in value from its one year high of $167.25. The RSI indicator value of 57.86, lead us to believe that it is a hold for now.

Berkshire Hathaway Inc. operates as a holding company. It provides property and casualty insurance and reinsurance, as well as life, accident, and health reinsurance; and operates railroad systems in North America. The company also generates, transmits, and distributes electricity from solar, wind, nuclear, geothermal, and hydro sources; operates natural gas distribution and storage facilities, interstate pipelines, and compressor and meter stations; and holds interest in coal mining assets. In addition, it offers real estate brokerage services; invests in fixed-income and equity instruments; and engages in manufactured housing and finance business, leasing of transportation equipment, and furniture leasing activities. Further, the company manufactures boxed chocolates and other confectionery products; specialty chemicals, metal cutting tools, and other products; flooring, insulation, roofing and engineered, building and engineered components, paint and coating, and bricks and masonry products; recreational vehicles, apparel products, jewelry, and custom picture framing products; and alkaline batteries. Additionally, it manufactures structural investment castings and forged components, machined airframe components and engineered critical fasteners; airfoil castings; titanium and nickel superalloy melted and mill products; and seamless pipes, fittings, and forgings. The company distributes newspapers, televisions, and information; franchises and services quick service restaurants; distributes electronic components; and offers steel and logistics services, professional aviation training programs, and fractional aircraft ownership programs. In addition, it retails automobiles; furniture, bedding, and accessories; household appliances, electronics, and computers; jewelry, watches, crystal, china, stemware, flatware, gifts, and collectibles; kitchen tools; and motorcycle apparel and equipment. The company was founded in 1889 and is headquartered in Omaha, Nebraska.

 

Momentum Stocks: AbbVie Inc. (ABBV), Sprint Corporation (S), Wal-Mart Stores, Inc. (WMT)

AbbVie Inc. (ABBV) retreated with the stock falling -2.07% or $-1.27 to close at $60 on light trading volume of 14.09M compared its three months average trading volume of 8.33M. The North Chicago Illinois 60064 based company operating under the Drug Manufacturers – Major industry has been trending up for the last 52 weeks, with the shares price now 11.54% up for the period and down by -3.22% so far this year. With price target of $69.94 and a 20.72% rebound from 52-week low, AbbVie Inc. has plenty of upside potential, making it a hold with a view buy.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Sprint Corporation (S) had a light trading with around 14.01M shares changing hands compared to its three month average trading volume of 18.94M. The stock traded between $9.22 and $9.47 before closing at the price of $9.22 with -2.23% change on the day. The Overland Park Kansas 66251 based company is currently trading 276.33% above its 52 week low of $2.45 and -2.74% below its 52 week high of $9.48. Both the RSI indicator and target price of  and $7.28 respectively, lead us to believe that it could rise over the coming weeks.

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells wireless devices, broadband devices, connected devices, and accessories to agents and other third-party distributors. The Wireline segment provides wireline voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies, and targeted business and consumer subscribers, as well as for cable multiple system operators. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

Wal-Mart Stores, Inc. (WMT) saw its value decrease by -1.6% as the stock dropped $-1.07 to finish the day at a closing price of $65.66. The stock was higher in trading and has fluctuated between $62.35-$75.19 per share for the past year. The shares, which traded within a range of $65.28 to $66.97 during the day, are down by -4.97% in the past three months and down by -9.09% over the past six months. It is currently trading -3.61% below its 20 day moving average and -5.48% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $74.05 a share over the next twelve months. The current relative strength index (RSI) reading is 31.79.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Wal-Mart Stores, Inc. operates retail stores in various formats worldwide. It operates through three segments: Walmart U.S., Walmart International, and Sam’s Club. The company operates discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, cash and carry stores, home improvement stores, specialty electronics stores, apparel stores, drug stores, convenience stores, and membership-only warehouse clubs; and retail Websites, such as walmart.com and samsclub.com. It offers grocery products, including meat, produce, natural and organics, deli and bakery, dairy, frozen foods, alcoholic and nonalcoholic beverages, floral and dry grocery, as well as consumables, such as health and beauty aids, baby products, household chemicals, paper goods, and pet supplies; and health and wellness products, which include pharmacy, optical services, clinical services, over-the-counter drugs, and other medical products. The company also provides electronics, toys, cameras and supplies, photo processing services, cellular phones, cellular service plan contracts and prepaid service, movies, music, video games, and books; stationery, automotive, hardware and paint, and sporting goods, as well as fabrics, crafts, and seasonal merchandise; apparel for women, girls, men, boys, and infants, as well as shoes, jewelry, and accessories; and home furnishings, housewares and small appliances, bedding, home decor, outdoor living, and horticulture products. The company also provides fuel and financial services and related products, including money orders, prepaid cards, wire transfers, money transfers, check cashing, and bill payment. In addition, it offers brand name merchandise, including hardgoods, softgoods, and selected private-label items, such as Member’s Mark. As of June 20, 2016, it operated 11,527 stores under 63 banners in 28 countries and e-commerce Websites in 11 countries. Wal-Mart Stores, Inc. was founded in 1945 and is headquartered in Bentonville, Arkansas.

 

Stocks on the Move: AbbVie Inc. (ABBV), Express Scripts Holding Company (ESRX), The Dow Chemical Company (DOW)

AbbVie Inc. (ABBV) managed to rebound with the stock climbing 1.32% or $0.8 to close the day at $61.38 on light trading volume of 8.04M shares, compared to its three month average trading volume of 8.26M. The North Chicago Illinois 60064 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 9.38%, compared to the industry which has advanced 2.3% over the same period. With RSI of 49.6, the stock should still continue to rise and get closer to its one year target estimate of $69.94, making it a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Express Scripts Holding Company (ESRX) fell -2.49% during last trading as the stock lost $-1.78 to finish the day at $69.62 with about 7.88M shares changing hands, compared to its three month average trading volume of 4.34M. The $43.35B market cap company, which fluctuated between $69.42 and $72.23 during the day, currently situated 8% above its 52 week low of $64.46 and -13% away from its one year high of $80.02. The RSI of 39.26 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. The company’s PBM segment’s products and services include clinical solutions to enhance health outcomes; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services, including design, implementation, and project management for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the use of medicines. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2015, the company operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy maintained for business continuity purpose, as well as several non-dispensing order processing centers, patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

The Dow Chemical Company (DOW) saw its value increase by 0.96% as the stock gained $0.57 to finish the day at a closing price of $60.21. The stock was higher in trading and has fluctuated between $40.69-$60.35 per share for the past year. The shares, which traded within a range of $59.35 to $60.35 during the day, are up by 11.88% in the past three months and up by 14.35% over the past six months. It is currently trading 4.13% above its 20 day moving average and 6.75% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $62.83 a share over the next twelve months. The current relative strength index (RSI) reading is 70. The technical indicator lead us to believe there will be no major movement any time soon, hold.

The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments. The Agricultural Sciences segment provides crop protection and seed/plant biotechnology products and technologies, urban pest management solutions, and healthy oils. The Consumer Solutions segment offers semiconductors and organic light-emitting diodes, and adhesives and foams used by the transportation industry; and cellulosics and other polymers for innovative pharmaceutical formulations and food solutions. It serves automotive, electronics and entertainment, food and pharmaceuticals, and personal and home care products markets. The Infrastructure Solutions segment provides architectural and industrial coatings, construction material ingredients, building insulation, adhesives, and microbial protection products for the oil and gas industry; water technologies; monomers; and silicone and silicone products. The Performance Materials & Chemicals segment offers chlorine and caustic soda; industrial solutions; and propylene oxides, propylene glycols, polyether polyols, and aromatic isocyanates. The Performance Plastics segment provides elastomers, polyolefin plastomers, and ethylene propylene diene monomer elastomers; wire and cable insulation, semiconductive, and jacketing compound solutions, as well as bio-based plasticizers; acrylics, polyethylene, polyolefin emulsions, and polyolefin plastomers; and ethylene, propylene, benzene, butadiene, cumene, octene, aromatics co-products, and crude c4. The company was founded in 1897 and is headquartered in Midland, Michigan.

 

Equities Trend Analysis: The Kroger Co. (KR), Pandora Media, Inc. (P), AbbVie Inc. (ABBV)

The Kroger Co. (KR) retreated with the stock falling -0.42% or $-0.14 to close at $33.39 on light trading volume of 6.92M compared its three months average trading volume of 8.02M. The Cincinnati Ohio 45202 based company operating under the Grocery Stores industry has been trending down for the last 52 weeks, with the shares price now -7.73% down for the period and down by -3.25% so far this year. With price target of $36 and a 16.73% rebound from 52-week low, The Kroger Co. has plenty of upside potential, making it a hold with a view buy.

The Kroger Co., together with its subsidiaries, operates as a retailer in the United States. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores. Its combination food and drug stores offer natural food and organic sections, pharmacies, general merchandise, pet centers, fresh seafood, and organic produce; multi-department stores provide general merchandise items, such as apparel, home fashion and furnishings, outdoor living, electronics, automotive products, toys, and fine jewelry; and price impact warehouse stores offer grocery, and health and beauty care items, as well as meat, dairy, baked goods, and fresh produce items. The company’s marketplace stores comprise full-service grocery, pharmacy, health and beauty departments, and perishable goods, as well as general merchandise, including apparel, home goods, and toys. It operates under the banner brands, such as Kroger, Ralphs, Fred Meyer, King Soopers, etc., as well as Simple Truth and Simple Truth Organic brands. As of January 30, 2016, the company operated 2,778 retail food stores, including 1,387 fuel centers; 784 convenience stores; and 323 fine jewelry stores and an online retail store, as well as franchised 78 convenience stores. The Kroger Co. was founded in 1883 and is headquartered in Cincinnati, Ohio.

Pandora Media, Inc. (P) had a light trading with around 6.83M shares changing hands compared to its three month average trading volume of 7.56M. The stock traded between $13.19 and $13.63 before closing at the price of $13.21 with -1.93% change on the day. The Oakland California 94612 based company is currently trading 86.06% above its 52 week low of $7.1 and -11.82% below its 52 week high of $14.98. Both the RSI indicator and target price of  and $14.48 respectively, lead us to believe that it could rise over the coming weeks.

Pandora Media, Inc. provides Internet music streaming services in North America. The company allows its listeners to create personalized stations to access free music and comedy catalogs, as well as personalized playlist generating system; and offers Pandora One, a paid subscription service to listeners. It also sells audio, display, and video advertising to advertisers for delivery on computer, mobile, and other connected device platforms. In addition, the company offers ticketing and marketing software and services for venues and event promoters to promote their events, as well as allow fans to find and purchase tickets for events. Pandora Media, Inc. was founded in 2000 and is headquartered in Oakland, California.

AbbVie Inc. (ABBV) saw its value decrease by -0.62% as the stock dropped $-0.38 to finish the day at a closing price of $60.58. The stock was lighter in trading and has fluctuated between $51.6-$68.12 per share for the past year. The shares, which traded within a range of $59.67 to $60.93 during the day, are up by 0.35% in the past three months and down by -3.99% over the past six months. It is currently trading -2.25% below its 20 day moving average and -1.07% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $69.94 a share over the next twelve months. The current relative strength index (RSI) reading is 44.05.The technical indicator lead us to believe there will be no major movement any time soon, hold.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

 

Worth Watching Stocks: AbbVie Inc. (ABBV), Twenty-First Century Fox, Inc. (FOXA), MannKind Corporation (MNKD)

AbbVie Inc. (ABBV) saw its value decrease by -0.31% as the stock dropped $-0.19 to finish the day at a closing price of $60.96. The stock was lighter in trading and has fluctuated between $51.6-$68.12 per share for the past year. The shares, which traded within a range of $60.68 to $61.26 during the day, are down by -0.3% in the past three months and down by -2.61% over the past six months. It is currently trading -1.63% below its 20 day moving average and -0.36% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $69.94 a share over the next twelve months. The current relative strength index (RSI) reading is 45.08.The technical indicator lead us to believe there will be no major movement any time soon, hold.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Twenty-First Century Fox, Inc. (FOXA) shares were down in last trading by -0.17% to $30. It experienced lighter than average volume on day. The stock decreased in value by almost -0.1% over the past week and grew 6.46% in the past month. It is currently trading 5.78% above its 50 day moving average and 10.21% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -3.26% decrease in value from its one year high of $31.25. The RSI indicator value of 62.21, lead us to believe that it is a hold for now.

Twenty-First Century Fox, Inc., together with its subsidiaries, operates as a diversified media and entertainment company in the United States, the United Kingdom, Continental Europe, Asia, Latin America, and internationally. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments. The company produces and licenses news, sports, movie, and general and factual entertainment programming for distribution primarily through cable television systems, direct broadcast satellite operators, telecommunications companies, and online video distributors. It also broadcasts network programming; and operates 28 broadcast television stations, including 11 duopolies in the United States. In addition, the company produces and acquires live-action and animated motion pictures for distribution and licensing in various formats and entertainment media, as well as produces and licenses television programming worldwide. Further, it offers video advertising services, including consumer engagement and on-demand marketing campaigns; and operates two San Francisco-Bay area television stations. The company was formerly known as News Corporation. Twenty-First Century Fox, Inc. was founded in 1922 and is headquartered in New York, New York.

MannKind Corporation (MNKD) traded within a range of $0.63 to $0.7 after opening the day at $0.64. The company has seen its stock increase in value by 8.37% so far this year. The stock was up close to 8.13% on light volume in last trading session and closed at $0.69 per share. After the recent gain, the stock is currently holding -69.2% below its 52 week high of $2.24 and 68.29% above its 12-month low of $0.41. The shares are up by over 13.17% in the last three months, and the RSI indicator value of 55.19 is neither bullish nor bearish, tempting investors to stay on the sidelines.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

 

Stocks Buzz: AbbVie Inc. (ABBV), Globalstar, Inc. (GSAT), The Kroger Co. (KR)

AbbVie Inc. (ABBV) continued its downward trend with the stock declining -0.32% or $-0.2 to close the day at $61.66 on light trading volume of 5.51M shares, compared to its three month average trading volume of 8.17M. The North Chicago Illinois 60064 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 16.42%, compared to the industry which has advanced 6.51% over the same period. With RSI of 48.8, the stock should still continue to rise and get closer to its one year target estimate of $70.11, making it a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Globalstar, Inc. (GSAT) retreated with the stock falling -2.76% or $-0.04 to close at $1.41 on light trading volume of 5.49M compared its three months average trading volume of 7.38M. The Covington Louisiana 70433 based company operating under the Wireless Communications industry has been trending up for the last 52 weeks, with the shares price now 30.56% up for the period and down by -10.76% so far this year. With price target of $6 and a 123.81% rebound from 52-week low, Globalstar, Inc. has plenty of upside potential, making it a hold with a view buy.

Globalstar, Inc. provides mobile voice and data communications services through satellite worldwide. The company offers duplex two-way voice and data products, including mobile voice and data satellite communications services and equipment for remote business continuity, recreational, emergency response, and other applications; fixed voice and data satellite communications services and equipment in rural villages, ships, industrial and commercial sites, and residential sites; and satellite data modem services comprising asynchronous and packet data services. It also provides SPOT products, such as SPOT satellite GPS messenger for personal tracking, emergency location, and messaging solutions; SPOT Global phone; and SPOT Trace, an anti-theft and asset tracking device. In addition, the company offers commercial Simplex one-way transmission products to track cargo containers and rail cars, to monitor utility meters, to monitor oil and gas assets, and other applications. Further, it provides engineering services, such as hardware and software designs to develop specific applications; and installation of gateways and antennas. The company primarily serves recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing; natural resources, mining, and forestry; construction; utilities; and transportation markets. Globalstar, Inc. distributes its products directly, as well as through independent agents, dealers and resellers, independent gateway operators, and its sales force and e-commerce Website. As of December 31, 2015, it served approximately 688,000 subscribers. The company has a collaboration agreement with Carmanah to design and manufacture solar powered M2M satellite solutions. The company was founded in 2003 and is headquartered in Covington, Louisiana. Globalstar, Inc. is a subsidiary of Thermo Funding II LLC.

The Kroger Co. (KR) continued its upward trend with the stock climbing 0.2% or $0.07 to close the day at $34.91 on lower than average trading volume of 5.4M shares, compared to its three month average trading volume of 8.23M. The Cincinnati Ohio 45202 based company has been outperforming the grocery stores companies by 13.5627% for last three months and its recent gains have pushed the stock slightly up 1.16% YTD, versus the grocery stores industry which is up 1.49% for the same period. The RSI of 59.38 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

The Kroger Co., together with its subsidiaries, operates as a retailer in the United States. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores. Its combination food and drug stores offer natural food and organic sections, pharmacies, general merchandise, pet centers, fresh seafood, and organic produce; multi-department stores provide general merchandise items, such as apparel, home fashion and furnishings, outdoor living, electronics, automotive products, toys, and fine jewelry; and price impact warehouse stores offer grocery, and health and beauty care items, as well as meat, dairy, baked goods, and fresh produce items. The company’s marketplace stores comprise full-service grocery, pharmacy, health and beauty departments, and perishable goods, as well as general merchandise, including apparel, home goods, and toys. It operates under the banner brands, such as Kroger, Ralphs, Fred Meyer, King Soopers, etc., as well as Simple Truth and Simple Truth Organic brands. As of January 30, 2016, the company operated 2,778 retail food stores, including 1,387 fuel centers; 784 convenience stores; and 323 fine jewelry stores and an online retail store, as well as franchised 78 convenience stores. The Kroger Co. was founded in 1883 and is headquartered in Cincinnati, Ohio.